With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.959795-70-1,4-(4-(4-Methylpiperazin-1-yl)piperidin-1-yl)aniline,as a common compound, the synthetic route is as follows.
959795-70-1, 2-Methanesulfmyl-7-(2-methoxy-phenyl)-pyrrolo[2, 1 -f] [ 1 ,2,4]triazine (125.0 mg, 0.0004350 mol), N,N-Dsopropylethylamine (0.114 mL, 0.000652 mol) and 4-[4-(4- Methyl-piperazin-l-yl)-piperidin-l-yl]-phenylamine (0.239 g, 0.000870 mol) were dissolved in l-Methoxy-2-propanol (1.2 mL, 0.013 mol) and the reaction was irradiated at 300 watts , 1800C for 40 minutes or until HPLC showed consumption of starting material. The reaction mixture was then reduced en vacuo and the product was isolated and purified by Gilson prep HPLC to afford 164.97 mg of [7-(2-Methoxy-phenyl)-pyrrolo[2,l- f][ 1 ,2,4]triazin-2-yl]- {4-[4-(4-methyl-piperazin- 1 -yl)-piperidin- 1 -yl]-phenyl} -amine as a lyophilized powder. (M+H) = 498.9. 1U NMR (400 MHz, DMSO, d6) delta 9.42 (s, IH), 8.94 (s, IH), 7.80 (dd, IH, J = 1.60, 6.00 Hz), 7.69 (d, 2H, J = 8.93 Hz), 7.46 (m, IH), 7.20 (d, IH, J = 8.28 Hz), 7.13 (m, 3H), 6.94 (m, 2H), 3.70 (s, 3H), 3.67 (m, 7H), 3.01 (m, 6H), 2.83 (s, 3H), 2.07 (m, 2H), 1.79 (m, 2H).
As the paragraph descriping shows that 959795-70-1 is playing an increasingly important role.
Reference£º
Patent; CEPHALON, INC.; BRESLIN, Henry J.; CHATTERJEE, Sankar; DIEBOLD, James L.; DORSEY, Bruce D.; DUNN, Derek; GINGRICH, Diane E.; HOSTETLER, Greg A.; HUDKINS, Robert L.; HUNTER, Rachael; JOSEF, Kurt; LISKO, Joseph; MESAROS, Eugen F.; MILKIEWICZ, Karen L.; OTT, Gregory R.; SUNDAR, Babu G.; THEROFF, Jay P.; THIEU, Tho; TRIPATHY, Rabindranath; UNDERINER, Theodore L.; WEINBERG, Linda; WELLS, Gregory J.; ZIFICSAK, Craig A.; WO2010/71885; (2010); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem